Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025. “This past quarter we continued to make steady progress across our pipeline, marked by the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected w